Mielóma multiplex: vizsgálatok itt: Japán
34 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Akita, Fukuoka, Kagoshima, Kumamoto, Nagasaki, Nagoya, Okayama, Osaka, Sendai, Shibukawa, Shibuya-ku, Sunto-gun, Tokushima, Yahaba-cho, Yamagata, Yoshida-gun
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - 1/2. fázisTaking peopleA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00 - 3. fázisNot yet taking people in JapánStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978 - 4. fázisTaking peopleElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Where
- Kyoto, Shibuya-ku
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00 - 1. fázisTaking peopleStudy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Bunkyo-ku, Kashiwa-shi, Koto-ku, Kumamoto, Mibu
- Életkor
- 18 év and over
- People
- 135 worldwide
- Run by
- AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00 - 3. fázisTaking peopleA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki, Ishikawa, Kanagawa, Miyagi, Nara, Numakunai, Osaka, Sapporo, Shibuya-Ku, Suita, Tokyo, Yamagata
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - 1/2. fázisNot yet taking people in JapánEque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
- Where
- Bunkyo-ku, Shibuya-ku, tabashi City
- Életkor
- 18 év to 70 év
- People
- 17
- Run by
- Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07510100 - 1/2. fázisTaking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Bunkyō City, Bunkyo-ku, Fukuoka, Fukushima, Hokkaido, Isehara-Shi, Kashiwa-shi, Miyagi, Nagasaki, Okayama, Osaka, Yoshida-gun
- Életkor
- 12 év and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555 - No phaseTaking peopleTransgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Where
- Kumamoto, Toyokawa
- People
- 50 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06357754